TEEM Therapeutics is an early-stage drug development company leveraging the power of human genetics in patient-derived stem cells and AI to identify new drug targets and develop novel drugs to stop atrial fibrillation at its source.

Founded by Kareen Coulombe, PhD , the company uses a validated, proprietary platform of tissue-engineered human mini-hearts backed by years of research and scientific publications. TEEM Therapeutics launched with funding from the Rhode Island Life Sciences Hub in late 2025 and has research operations established at Ocean State Labs in Providence, RI.

We are raising pre-seed funds and seeking partners to advance our mission to develop new selective anti-arrhythmic drugs. Contact us to get involved.